Personalizing Endocrine Therapy Plans: Help Patients with Early-Stage, HR+ Breast Cancer Find Clarity About What’s Next

Editor's Note: The following article was originally written and shared with us by Adriana Olivo, NP, Memorial Sloan Kettering Cancer Center. For many people with hormone receptor-positive (HR+), early-stage breast…

Continue Reading Personalizing Endocrine Therapy Plans: Help Patients with Early-Stage, HR+ Breast Cancer Find Clarity About What’s Next

Alentis Deepens ADC Strategy Through New Claudin-1 Collaboration With PinotBio

As reported on Pharmaceutical Technology, Alentis Therapeutics has expanded its efforts in claudin-1-targeted cancer therapeutics through a newly announced partnership with PinotBio, aimed at generating antibody-drug conjugates (ADCs) for multiple…

Continue Reading Alentis Deepens ADC Strategy Through New Claudin-1 Collaboration With PinotBio

Otsuka’s Phase 3 VISIONARY Study Suggests Voyxact May Alter Disease Course in IgA Nephropathy

Final two-year data from the Phase 3 VISIONARY trial indicate that Voyxact (sibeprenlimab-szsi) may significantly slow progression of primary immunoglobulin A nephropathy (IgAN), preserving kidney function and reducing the likelihood…

Continue Reading Otsuka’s Phase 3 VISIONARY Study Suggests Voyxact May Alter Disease Course in IgA Nephropathy

Alliance Announces FDA Approval of Atezolizumab Based on Results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer

Editor's Note: This article, reprinted in full, was originally written and shared with us by Alliance. To see the article in its original format, please click here. The Alliance for…

Continue Reading Alliance Announces FDA Approval of Atezolizumab Based on Results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer

FDA Approves Belzutifan Plus Lenvatinib for Previously Treated Advanced Clear Cell Renal Cell Carcinoma

As reported on PharmaBiz, the US Food and Drug Administration (FDA) has approved the oral combination of belzutifan (Welireg) and lenvatinib (Lenvima) for adults with advanced renal cell carcinoma (RCC)…

Continue Reading FDA Approves Belzutifan Plus Lenvatinib for Previously Treated Advanced Clear Cell Renal Cell Carcinoma

AstraZeneca Expands AI-Driven Drug Discovery Efforts in MASH and Cardiomyopathy

As reported on BioSpace, AstraZeneca has entered a major artificial intelligence-focused research collaboration with biotechnology company insitro, committing up to $1.5 billion in potential payments to identify new drug targets…

Continue Reading AstraZeneca Expands AI-Driven Drug Discovery Efforts in MASH and Cardiomyopathy

Bristol Myers Squibb Wins FDA Expansion for Camzyos in Pediatric Obstructive Hypertrophic Cardiomyopathy

As reported on Yahoo! News, Bristol Myers Squibb (BMS) has received an expanded approval from the US Food and Drug Administration (FDA) for Camzyos (mavacamten), extending its use to pediatric…

Continue Reading Bristol Myers Squibb Wins FDA Expansion for Camzyos in Pediatric Obstructive Hypertrophic Cardiomyopathy

Ebola – Lessons Learned

The Ebola outbreak in DR Congo was declared in May 2026. As reported in BBC News, authorities in DR Congo recently confirmed that the virus is spreading at an alarming…

Continue Reading Ebola – Lessons Learned